Our Medicines

Through development and commercialization partnerships, Sosei Heptares has already delivered two products to treat chronic obstructive pulmonary disease (COPD) and a treatment for orapharyngeal candidiasis. The legacy Novartis franchise continues to generate significant and stable revenue streams that enable further growth of the business.


Ultibro® Breezhaler®
Indication:  COPD
Partner:  Novartis

Seebri® Breezhaler®
Indication:  COPD
Partner:  Novartis

Enerzair® Breezhaler®
Indication:  Asthma
Partner:  Novartis

ORAVI®
Indication:  Oropharyngeal candidiasis
Partner:  Hisamitsu Pharmaceutical Co.,Inc.